HIGH POINT, N.C., Oct. 06, 2026 (GLOBE NEWSWIRE) — vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company advancing cadisegliatin, a novel oral investigational therapy for type 1 diabetes (T1D), today announced that it will host a virtual key opinion leader (KOL) event on Tuesday, October 20, 2026, at 2:30 PM ET. To register, click here.
The event will feature leading T1D experts Schafer Boeder, MD (Paradigm Clinical Research, University of California San Diego), Klara Klein, MD, PhD (University of North Carolina at Chapel Hill School of Medicine), and acclaimed cellist and T1D advocate Alisa Weilerstein. Together, they will join company management to discuss:
Ongoing challenges for individuals living with T1D and the current treatment landscape
Hypoglycemia risk and the experience of living with T1D
Cadisegliatin, vTv’s novel, potential first-in-class oral liver-selective glucokinase activator being investigated as an adjunctive therapy to insulin in T1D
An overview of the ongoing Phase 3 CATT1 trial evaluating cadisegliatin as an oral adjunctive therapy to insulin in T1D with topline data expected in mid 2027
A live question-and-answer session will follow the formal presentations. Following the event, a replay will be available in the Investor Relations section of the Company’s website.
About Schafer Boeder, MD
Schafer Boeder, MD, is a board-certified endocrinologist, Medical Director at Paradigm Clinical Research, and Associate Professor of Medicine at the University of California San Diego. His clinical research focuses on the development of new medications, devices, and technologies for diabetes, obesity, and related metabolic diseases. He has served as principal investigator for numerous industry-, NIH-, and nonprofit-sponsored clinical trials and has published extensively in diabetes and metabolism. Dr. Boeder earned his medical degree from Eastern Virginia Medical School and completed his residency in internal medicine and fellowship in endocrinology, diabetes, and metabolism at UC San Diego.
About Klara Klein, MD, PhD
Klara Klein, MD, PhD, is an Assistant Professor in the Division of Endocrinology and Metabolism at the University of North Carolina at Chapel Hill and Director of the Endocrine Diabetes and Obesity Clinical Research Unit (EnDO CRU). A clinician-scientist, Dr. Klein oversees industry-sponsored and investigator-initiated clinical trials in metabolic diseases. Her research interests include atypical diabetes, diabetes in advanced chronic kidney disease, and stakeholder-engaged clinical trials designed to improve the reach and representativeness of clinical research. Dr. Klein is also actively involved in type 1 diabetes research and is a co-author of the UpToDate clinical topic on glycemic management in adults with type 1 diabetes.
Story Continues
